Iterion Therapeutics
BioTech/Drugs - Houston, TX, US
Iterion Therapeutics Employees
Iterion Therapeutics Senior Management
Iterion Therapeutics Details
Iterion Therapeutics is a clinical stage biopharmaceutical company focused on developing novel cancer therapeutics. The company's lead product, tegavivint, is a highly specific and potent first-in-class small molecule inhibitor of TBL1 (Transducin Beta-Like Protein 1), a novel downstream target of the canonical Wnt/beta-catenin signaling pathway. Iterion is advancing clinical programs of tegavivint in tumor types with a high prevalence of Wnt/beta-catenin activating mutations, such as hepatocellular carcinoma. In parallel, the company has deep collaborative relationships with leading institutions studying tegavivint in complementary investigator-sponsored trials in acute myeloid leukemia, non small cell lung cancer, pediatric tumors and lymphoma.
Iterion Therapeutics Technologies
Email Providers
Outlook
Load Balancers
Nginx
CMS
WordPress.org
Hosting
Amazon AWS
Other
Microsoft Office 365